JAZZ PHARMACEUTICALS PLC (JAZZ)

IE00B4Q5ZN47 - Common Stock

105.59  -0.45 (-0.42%)

After market: 105.59 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (7/12/2024, 3:30:02 PM)

After market: 105.59 0 (0%)

105.59

-0.45 (-0.42%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-11.22%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap6.66B
Shares
PE6.19
Fwd PE4.97
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

JAZZ Daily chart

Company Profile

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The firm is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Company Info

JAZZ PHARMACEUTICALS PLC

Fifth Fl, Waterloo Exchange, Waterloo Road

DUBLIN DUBLIN D04

P: 35316347800

CEO: Bruce C. Cozadd

Employees: 2800

Website: https://www.jazzpharma.com/

JAZZ News

News Image4 days ago - Jazz Pharmaceuticals plcJazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Samantha Pearce, Senior Vice President (SVP), Europe and International, has been...

News Image9 days ago - InvestorPlace3 Mid-Cap Growth Rockets Trading at Deep Discounts to Their Potential

Large cap stocks are where the alpha is now, but there’s a case to be made for these undervalued mid-cap growth stocks

News Image16 days ago - InvestorPlace7 Biotech Stocks to Boost Your Portfolio to Peak Health

With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas.

News Image17 days ago - InvestorPlace3 Cannabis Stocks That Could Make Your Grandchildren Rich

These cannabis stocks offer long-term growth potential anchored by solid operational models and diversified revenue streams today.

News Image23 days ago - Investor's Business DailyJazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure

The companies are working on treatments for essential tremor, a tricky indication.

News Image23 days ago - Jazz Pharmaceuticals plcJazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial (NCT05122650) evaluating the efficacy...

JAZZ Twits

Here you can normally see the latest stock twits on JAZZ, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example